In the CREDENCE trial, eGFR slope per year was −4.6 ml/min in patients with T2D and kidney disease, while treatment with the SGLT-2 inhibitor canagliflozin led to an eGFR slope reduction by 2.7 ml/min per year (eGFR slope − 1.85 ml/min per year) [24]. This evidence concerns the gene SLC5A2 and kidney disorder.